Metformin and Vascular Diseases: A Focused Review on Smooth Muscle Cell Function
Open Access
- 8 May 2020
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 11, 635
Abstract
Metformin has been used in diabetes for more than 60 years and has excellent safety in the therapy of human type 2 diabetes (T2D). There is growing evidence that the beneficial health effects of metformin are beyond its ability to improve glucose metabolism. Metformin not only reduces the incidence of cardiovascular diseases (CVD) in T2D patients, but also reduces the burden of atherosclerosis (AS) in pre-diabetes patients. Vascular smooth muscle cells (VSMCs) function is an important factor in determining the characteristics of the entire arterial vessel. Its excessive proliferation contributes to the etiology of several types of CVD, including AS, restenosis, and pulmonary hypertension. Current studies show that metformin has a beneficial effect on VSMCs function. Therefore, this review provides a timely overview of the role and molecular mechanisms by which metformin acts through VSMCs to protect CVD.Keywords
Funding Information
- Innovative Research Group Project of the National Natural Science Foundation of China
This publication has 112 references indexed in Scilit:
- Increased Methylglyoxal Formation with Upregulation of Renin Angiotensin System in Fructose Fed Sprague Dawley RatsPLOS ONE, 2013
- The protective effect and underlying mechanism of metformin on neointima formation in fructose-induced insulin resistant ratsCardiovascular Diabetology, 2013
- mTOR is required for pulmonary arterial vascular smooth muscle cell proliferation under chronic hypoxiaThe FASEB Journal, 2011
- Hyaluronan Synthesis Is Inhibited by Adenosine Monophosphate-activated Protein Kinase through the Regulation of HAS2 Activity in Human Aortic Smooth Muscle CellsJournal of Biological Chemistry, 2011
- Smooth Muscle Cell Hypertrophy, Proliferation, Migration and Apoptosis in Pulmonary Hypertension2010
- Protective role of the antidiabetic drug metformin against chronic experimental pulmonary hypertensionBritish Journal of Pharmacology, 2009
- Metformin Inhibits Proinflammatory Responses and Nuclear Factor-κB in Human Vascular Wall CellsArteriosclerosis, Thrombosis, and Vascular Biology, 2006
- Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetesDiabetic Medicine, 2005
- Vascular calcification—a passive process in need of inhibitorsNephrology Dialysis Transplantation, 2000
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)The Lancet, 1998